RMC-6291 for Solid Cancers
Trial Summary
What is the purpose of this trial?
This trial tests a new drug, RMC-6291, in adults with advanced cancers that have a specific mutation. The drug aims to block a faulty protein in these cancer cells to stop their growth.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What makes the drug RMC-6291 unique for treating solid cancers?
RMC-6291 is unique because it targets specific components of cancer cells, potentially involving mechanisms related to ribonucleotide reductase subunits like RRM2B, which have been associated with better survival outcomes in certain cancers. This approach may offer a novel way to suppress cancer cell invasiveness and improve patient prognosis compared to traditional treatments.12345
Research Team
Revolution Medicines, Inc.
Principal Investigator
Revolution Medicines, Inc.
Eligibility Criteria
Adults over 18 with advanced solid tumors that have a specific mutation (KRASG12C) can join. They should have tried standard treatments, be in fairly good health, and able to do daily activities. Not for those who've had recent surgery or brain tumors/metastases.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive escalating doses of RMC-6291 to evaluate safety, tolerability, and pharmacokinetics
Dose Expansion
Participants receive the recommended Phase 2 dose of RMC-6291 to further evaluate safety and efficacy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- RMC-6291
Find a Clinic Near You
Who Is Running the Clinical Trial?
Revolution Medicines, Inc.
Lead Sponsor